Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 3, 2007, Pages 678-684

  Cohen, Ezra E W ^a,b   Rosine, Dominique ^c   Haraf, Daniel J ^a,b   Loh, Elwyn ^d   Shen, Liji ^d   Lusinchi, Antoine ^c   Vokes, Everett E ^a,b   Bourhis, Jean ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of Chicago   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Sanofi Research Division   (United States)

Author keywords

Hypoxic cell sensitizer; Recurrent head and neck cancer; Reirradiation; Tirapazamine

Indexed keywords

CELLS; CHEMOTHERAPY; PATIENT MONITORING; TOXICITY; TUMORS;

HYPOXIC CELL SENSITIZER; RECURRENT HEAD-AND-NECK CANCER; REIRRADIATION; TIRAPAZAMINE;

RADIOTHERAPY;

CISPLATIN; TIRAPAZAMINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASPIRATION PNEUMONIA; ASTHENIA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CATHETER INFECTION; CLINICAL TRIAL; COHORT ANALYSIS; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DERMATITIS; DIARRHEA; FATALITY; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MUSCLE SPASM; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RADIATION DOSE; STOMATITIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; RETREATMENT; TRIAZINES;

EID: 33846796400     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.09.056     Document Type: Article

References (22)

1. Seiwert T.Y., and Cohen E.E. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92 (2005) 1341-1348
2. Cohen E.E., Lingen M.W., and Vokes E.E. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 22 (2004) 1743-1752
3. Chmura S.J., Milano M.T., and Haraf D.J. Reirradiation of recurrent head and neck cancers with curative intent. Semin Oncol 31 (2004) 816-821
4. Peters K.B., and Brown J.M. Tirapazamine: A hypoxia-activated topoisomerase II poison. Cancer Res 62 (2002) 5248-5253
5. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., and Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 (1997) 285-289
6. Craighead P.S., Pearcey R., and Stuart G. A Phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 48 (2000) 791-795
7. Rischin D., Peters L., Hicks R., et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19 (2001) 535-542
8. Rischin D., Peters L., Fisher R., et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23 (2005) 79-87
9. Rischin D., Hicks R.J., Fisher R., et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24 (2006) 2098-2104
10. Hellman S., and Weichselbaum R.R. Oligometastases. J Clin Oncol 13 (1995) 8-10
11. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
12. Miller V.A., Ng K.K., Grant S.C., et al. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 8 (1997) 1269-1271
13. De Crevoisier R., Bourhis J., Domenge C., et al. Full-dose reirradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 16 (1998) 3556-3562
14. De Crevoisier R., Domenge C., Wibault P., et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer 91 (2001) 2071-2076
15. Hehr T., Classen J., Belka C., et al. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: A prospective Phase I/II trial. Int J Radiat Oncol Biol Phys 61 (2005) 1423-1431
16. Machtay M., Rosenthal D.I., Chalian A.A., et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 59 (2004) 72-77
17. Spencer S.A., Harris J., Wheeler R.H., et al. RTOG 96-10: Reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 51 (2001) 1299-1304
18. Kramer N.M., Horwitz E.M., Cheng J., et al. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck 27 (2005) 406-414
19. Salama J.K., Vokes E.E., Chmura S.J., et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 64 (2006) 382-391
20. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46 (1998) 135-146
21. Overgaard J., Eriksen J.G., Nordsmark M., Alsner J., and Horsman M.R. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6 (2005) 757-764
22. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735